david read this from cygx latest Pr outside validation
david key word Dr. Michael Chambers, President and CEO of Aldevron. "One of our goals is to help expand the field of DNA-based pharmaceuticals.
CytoGenix Receives First Order for synDNA(TM)
CytoGenix, Inc. (OTCBB:CYGX) announced receiving its first purchase order for synDNA(TM) synthetic DNA. The order was placed by Aldevron (Fargo, North Dakota), a leading worldwide supplier of DNA for research and clinical applications. CytoGenix and Aldevron have joined forces to meet the special needs of the market for multi-gram quantities of highly pure DNA.
"The CytoGenix synDNA(TM) technology allows us to offer a broader range of solutions to gene therapy and DNA vaccine researchers," said Dr. Michael Chambers, President and CEO of Aldevron. "One of our goals is to help expand the field of DNA-based pharmaceuticals. We welcome the relationship with CytoGenix and look forward to working together to expand the market for high quality DNA."
Plasmid DNA is commonly used to make many copies of a particular gene. These genes are used by researchers to test DNA-based treatments for a wide range of diseases. Traditionally, plasmid DNA is manufactured via a complex process that involves processing bacteria to yield high-grade amounts of plasmid DNA. CytoGenix' product is produced synthetically, and no bacteria are required, thereby speeding the production time and increasing the purity and quality of the DNA.
Dr. Malcolm Skolnick, President and CEO commented, "This is a major milestone for CytoGenix. While our primary goal is to develop our own products, we are pleased to service the growing need for high purity cost-effective DNA. We are very excited about our relationship with Aldevron and the opportunity to supply their needs for synDNA(TM)."
